Cover Image
市場調查報告書

PharmaPoint:第二型糖尿病 - 全球醫藥品市場預測與市場分析

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 298049
出版日期 內容資訊 英文 377 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:第二型糖尿病 - 全球醫藥品市場預測與市場分析 PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年07月19日 內容資訊: 英文 377 Pages
簡介

主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本) 、新興國家 (中國、印度) 的第二型糖尿病的治療藥市場,預計從2015年的312億美元,到2025年擴大到587億美元。市場預計2015年∼2025年以6.5%的年複合成長率成長。

本報告提供第二型糖尿病的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因
  • 病理生理學
  • 預後
  • QOL
  • 症狀

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
    • 中國、印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學預測
    • 確診的患者數
    • 確診的患者數 (各年齡)
    • 確診的患者數 (性別)
    • 確診的患者數 (年齡調整) 等
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Metformin
    • 磺醯尿素類,其他胰島素分泌促進藥
    • αGlucosidase抑制劑 (AGI)
    • 胰島素增敏劑 (TZD)
    • GLP-1受體激動劑
    • DPP-4抑制劑
    • SGLT-2抑制劑
    • 胰島素製劑

第7章 未滿足需求和機會

  • 概要
  • 提供永續的血糖管理的病理修飾療法
  • 血糖作用沒有的藥物
  • 副作用改善的藥物
  • 患者的藥物服用遵守增加

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的潛力藥物

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Eli Lilly
    • Novo Nordisk
    • Sanofi
    • GlaxoSmithKline
    • AstraZeneca
    • Merck & Co.
    • Boehringer Ingelheim
    • 武田藥品工業
    • Roche
    • Pfizer
    • Johnson & Johnson
    • Novartis
    • Intarcia Therapeutics

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國
  • 印度

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC152PIDR

Type 2 diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic B-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle (Stumvoll et al., 2010). It is well recognized that many of the current therapies for T2D are generally unable to alter its natural course, with glycemic control typically deteriorating over time. This often results in increasingly complicated treatment regimens (Inzucchi et al., 2012). In the US, T2D is the leading cause of blindness, kidney failure, non-traumatic lower-limb amputations, cardiovascular disease (CVD), and mortality (Sarwar et al., 2010). It is a major cause of heart disease and stroke and is the seventh-leading cause of death among US adults.

Global Type 2 Diabetes (T2D) pharmaceutical market in the base year 2016 was $28.6B, including both branded and generic drugs. Branded products alone accounted for $23.8B across the 7MM. At 71% of the overall T2D market, the US is clearly the dominant market, totaling $20.3B in branded and generic pharmaceutical sales. This is due to the much higher prices of pharmaceuticals in this country and due to the highly diagnosed prevalence of T2D.

Over the forecast period of 2016-2026, the global T2D market will double, reaching $64.0B at a Compound Annual Growth Rate (CAGR) of 8.4%. The US will continue to grow in size most rapidly due to a dramatic increase in T2D prevalence and diagnosis, which is attributed to increased life expectancy and lifestyle changes. The US will increase its global market share from 71% to 74%, stealing market share predominantly from Japan, which will account for 9% of the overall T2D market in 2026. Sales in the US will grow by approximately 8.9% per year over the forecast period.

The report "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026" focuses on the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), also referred to as the "global market".

This report provides the following information in-depth -

  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Adocia, Astellas Pharma, AstraZeneca, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb, Chong Kun Dang, Chugai Pharmaceuticals, Daiichi Sankyo, Diasome, Eli Lilly, GlaxoSmithKline, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson

Scope

  • Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global T2D therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 10

2 Type 2 Diabetes (T2D): Executive Summary 11

  • 2.1 T2D Sales to Double Across 7MM 12
  • 2.2 Multiple Opportunities Exist to Address Existing T2D Market Unmet Needs 14
  • 2.3 The Arrival of Insulin Biosimilars and Abundance of "Me-Too" Drugs Illustrates Corporate Shift in Focus from Therapeutic Value Towards Competitive Pricing and Non-novel Agents that Confer Incremental Benefits 18
  • 2.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs' Ability to Improve Patient Compliance/Ease of Administration and Cardiovascular Effects 19
  • 2.5 Newest T2D Drug Class, Sodium-Glucose Cotransporter Inhibitors, Will Continue To Gain Significant Market Share Despite Concerns 19
  • 2.6 What Do Physicians Think? 20

3 Introduction 23

  • 3.1 Catalyst 23
  • 3.2 Related Reports 24

4 Disease Overview 25

  • 4.1 Etiology 25
  • 4.2 Pathophysiology 27
  • 4.3 Symptoms 29
  • 4.4 Prognosis 31
  • 4.5 Quality of Life 31

5 Epidemiology 31

  • 5.1 Disease Background 32
  • 5.2 Risk Factors and Comorbidities 32
  • 5.3 Global and Historical Trends 34
  • 5.4 Forecast Methodology 35
    • 5.4.1 Sources Used 36
    • 5.4.2 Forecast Assumptions and Methods 39
  • 5.5 Epidemiological Forecast for T2D in the 8MM (2016-2026) 48
    • 5.5.1 Diagnosed Prevalent Cases of T2D 48
    • 5.5.2 Age-Specific Diagnosed Prevalent Cases of T2D 49
    • 5.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D 49
    • 5.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D 50
  • 5.6 Discussion 54
    • 5.6.1 Epidemiological Forecast Insight 54
    • 5.6.2 Limitations of Analysis 55
    • 5.6.3 Strengths of Analysis 55

6 Disease Management 57

  • 6.1 Diagnosis and Treatment Overview 57
    • 6.1.1 Diagnosis and Referrals 57
    • 6.1.2 Treatment Guidelines and Leading Prescribed Drugs 58
    • 6.1.3 Clinical Practice 63
  • 6.2 US 64
  • 6.3 France 66
  • 6.4 Germany 68
  • 6.5 Italy 71
  • 6.6 Spain 75
  • 6.7 UK 78
  • 6.8 Japan 82

7 Competitive Assessment 86

  • 7.1 Overview 86
  • 7.2 Strategic Competitor Assessment 86
  • 7.3 Product Profiles - Major Brands 89
    • 7.3.1 Metformin 89
    • 7.3.2 Sulfonylureas and Other Insulin Secretagogues 93
    • 7.3.3 α-glucosidase Inhibitors 97
    • 7.3.4 Thiazolidinediones 100
    • 7.3.5 Glucagon-Like Peptide-1 Receptor Agonists 104
    • 7.3.6 Dipeptidyl-Peptidase 4 Inhibitors 131
    • 7.3.7 Sodium-Glucose Cotransporter 2 Inhibitors 165
    • 7.3.8 Insulin Formulations 184

8 Unmet Needs and Opportunities 221

  • 8.1 Overview 221
  • 8.2 Disease-Modifying Treatments Providing Sustained Glycemic Control 222
    • 8.2.1 Unmet Need 222
    • 8.2.2 Gap Analysis 223
    • 8.2.3 Opportunity 224
  • 8.3 Drugs with Non-Glycemic Benefits 224
    • 8.3.1 Unmet Need 224
    • 8.3.2 Gap Analysis 224
    • 8.3.3 Opportunity 225
  • 8.4 Drugs with Improved Side-Effect Profiles 225
    • 8.4.1 Unmet Need 225
    • 8.4.2 Gap Analysis 226
    • 8.4.3 Opportunity 226
  • 8.5 Increased Patient Compliance 226
    • 8.5.1 Unmet Need 226
    • 8.5.2 Gap Analysis 227
    • 8.5.3 Opportunity 228

9 Pipeline Assessment 229

  • 9.1 Overview 229
  • 9.2 Clinical Trial Mapping 230
    • 9.2.1 Clinical Trials by Country 230
    • 9.2.2 Clinical Trials by Phase and Trial Status 231
  • 9.3 Promising Drugs in Clinical Development 232
    • 9.3.1 Semaglutide 235
    • 9.3.2 OG217SC/Semaglutide (oral) 239
    • 9.3.3 ITCA 650 241
    • 9.3.4 Ertugliflozin 245
    • 9.3.5 Sotagliflozin 249
    • 9.3.6 Bexagliflozin 252

10 Current and Future Players 256

  • 10.1 Overview 256
  • 10.2 Trends in Corporate Strategy 260
  • 10.3 Company Profiles 262
    • 10.3.1 Eli Lilly 262
    • 10.3.2 Novo Nordisk 265
    • 10.3.3 Sanofi 268
    • 10.3.4 AstraZeneca 271
    • 10.3.5 Merck & Co. 273
    • 10.3.6 Boehringer Ingelheim 274
    • 10.3.7 GlaxoSmithKline 276
    • 10.3.8 Takeda 278
    • 10.3.9 Roche 279
    • 10.3.10 Pfizer 280
    • 10.3.11 Johnson & Johnson 282
    • 10.3.12 Novartis 283
    • 10.3.13 Intarcia Therapeutics 284
    • 10.3.14 Theracos 285

11 Market Outlook 287

  • 11.1 Global Markets 287
    • 11.1.1 Forecast 287
    • 11.1.2 Drivers and Barriers - Global Issues 290
  • 11.2 US 291
    • 11.2.1 Forecast 291
    • 11.2.2 Key Events 293
    • 11.2.3 Drivers and Barriers 294
  • 11.3 France 295
    • 11.3.1 Forecast 295
    • 11.3.2 Key Events 297
    • 11.3.3 Drivers and Barriers 297
  • 11.4 Germany 299
    • 11.4.1 Forecast 299
    • 11.4.2 Key Events 301
    • 11.4.3 Drivers and Barriers 301
  • 11.5 Italy 303
    • 11.5.1 Forecast 303
    • 11.5.2 Key Events 305
    • 11.5.3 Drivers and Barriers 305
  • 11.6 Spain 307
    • 11.6.1 Forecast 307
    • 11.6.2 Key Events 309
    • 11.6.3 Drivers and Barriers 309
  • 11.7 UK 311
    • 11.7.1 Forecast 311
    • 11.7.2 Key Events 313
    • 11.7.3 Drivers and Barriers 313
  • 11.8 Japan 315
    • 11.8.1 Forecast 315
    • 11.8.2 Key Events 317
    • 11.8.3 Drivers and Barriers 318

12 Appendix 320

  • 12.1 Bibliography 320
  • 12.2 Abbreviations 351
  • 12.3 Methodology 358
  • 12.4 Forecasting Methodology 358
    • 12.4.1 Diagnosed T2D Patients 358
    • 12.4.2 Percent Drug-Treated Patients 358
    • 12.4.3 Drugs Included in Each Therapeutic Class 358
    • 12.4.4 Launch and Patent Expiry Dates 359
    • 12.4.5 General Pricing Assumptions 359
    • 12.4.6 Individual Drug Assumptions 360
    • 12.4.7 Generic Erosion 371
    • 12.4.8 Pricing of Pipeline Agents 371
  • 12.5 Physicians and Specialists Included in this Study 371
  • 12.6 About the Authors 374
    • 12.6.1 Managing Analyst 374
    • 12.6.2 Therapy Area Director 374
    • 12.6.3 Epidemiologists 374
    • 12.6.4 Global Director of Therapy Analysis and Epidemiology 376
    • 12.6.5 Global Head and EVP of Healthcare Operations and Strategy 376
  • 12.7 About GlobalData 377
  • 12.8 Contact Us 377
  • 12.9 Disclaimer 377

List of Tables

1.1 List of Tables

  • Table 1: T2D: Key Metrics in the Seven Major Pharmaceutical Markets 11
  • Table 2: Overall Unmet Needs - Current Level of Attainment 15
  • Table 3: Primary pathophysiologic conditions associated with T2D 28
  • Table 4: Symptoms of T2D 30
  • Table 5: Risk Factors and Comorbidities for T2D. 33
  • Table 6: 7MM, Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, Selected Years 2016-2026 48
  • Table 7: Diagnostic Tests and Typical Criteria for Diagnosing T2D 57
  • Table 8: T2D Treatments 60
  • Table 9: Country Profile, T2D Management, US 65
  • Table 10: Country Profile, T2D Management, France 67
  • Table 11: Country Profile, T2D Management, Germany 70
  • Table 12: Country Profile, T2D Management, Italy 74
  • Table 13: Country Profile, T2D Management, Spain 77
  • Table 14: Country Profile, T2D Management, UK 81
  • Table 15: Country Profile, T2D Management, Japan 84
  • Table 16: Leading Branded Treatments for T2D, 2016 88
  • Table 17: Product Profile - Metformin 90
  • Table 18: Metformin SWOT Analysis, 2016 92
  • Table 19: First-Generation SUs 94
  • Table 20: Second-Generation SUs 94
  • Table 21: : Product Profile - SUsTable 26 95
  • Table 22: SUs SWOT Analysis, 2016 96
  • Table 23: Product Profile - Acarbose 98
  • Table 24: AGIs SWOT Analysis, 2016 100
  • Table 25: Product Profile - Actos 102
  • Table 26: TZDs SWOT Analysis, 2016 104
  • Table 27: GLP-1RAs 106
  • Table 28: Product Profile - Byetta 108
  • Table 29: Byetta SWOT Analysis, 2016 110
  • Table 30: Product Profile - Victoza 112
  • Table 31: Victoza SWOT Analysis, 2016 114
  • Table 32: Product Profile - Bydureon 116
  • Table 33: Bydureon SWOT Analysis, 2016 118
  • Table 34: Product Profile - Lyxumia 120
  • Table 35: Lyxumia SWOT Analysis, 2016 122
  • Table 36: Product Profile - Tanzeum 124
  • Table 37: Tanzeum SWOT Analysis, 2016 127
  • Table 38: Product Profile - Trulicity 128
  • Table 39: Trulicity SWOT Analysis, 2016 131
  • Table 40: Marketed DPP-4Is 134
  • Table 41: Marketed DPP-4Is in Combination with Other OADs 134
  • Table 42: Product Profile - Januvia 136
  • Table 43: Januvia SWOT Analysis, 2016 138
  • Table 44: Product Profile - Onglyza 140
  • Table 45: Onglyza SWOT Analysis, 2016 142
  • Table 46: Product Profile - Tradjenta 144
  • Table 47: Tradjenta SWOT Analysis, 2016 146
  • Table 48: Product Profile - Galvus 148
  • Table 49: Galvus SWOT Analysis, 2016 150
  • Table 50: Product Profile - Nesina 152
  • Table 51: Nesina SWOT Analysis, 2016 153
  • Table 52: Product Profile - Tenelia 155
  • Table 53: Tenelia SWOT Analysis, 2016 157
  • Table 54: Product Profile - Suiny 158
  • Table 55: Suiny SWOT Analysis, 2016 159
  • Table 56: Product Profile - Zafatek 160
  • Table 57: Zafatek SWOT Analysis, 2016 162
  • Table 58: Product Profile - Marizev 164
  • Table 59: Marizev SWOT Analysis, 2016 165
  • Table 60: SGLT-2Is 167
  • Table 61: Marketed SGLT-2Is in Combination with Other T2D Drugs 167
  • Table 62: Product Profile - Forxiga 168
  • Table 63: Forxiga SWOT Analysis, 2016 170
  • Table 64: Product Profile - Invokana 171
  • Table 65: Invokana SWOT Analysis, 2016 173
  • Table 66: Product Profile - Jardiance 174
  • Table 67: Jardiance SWOT Analysis, 2016 177
  • Table 68: Product Profile - Apleway 178
  • Table 69: Apleway SWOT Analysis, 2016 179
  • Table 70: Product Profile - Suglat 181
  • Table 71: Suglat SWOT Analysis, 2016 182
  • Table 72: Product Profile - Lusefi 183
  • Table 73: Lusefi SWOT Analysis, 2016 184
  • Table 74: Insulins - Overview and Comparison 186
  • Table 75: Marketed Combination Insulins 186
  • Table 76: Insulin Formulations 186
  • Table 77: Product Profile - Humalog 187
  • Table 78: Humalog SWOT Analysis, 2016 189
  • Table 79: Product Profile - Lantus 191
  • Table 80: Lantus SWOT Analysis, 2016 193
  • Table 81: Toujeo SWOT Analysis, 2016 197
  • Table 82: Product Profile - Levemir 198
  • Table 83: Levemir SWOT Analysis, 2016 200
  • Table 84: Product Profile - NovoLog 201
  • Table 85: NovoLog SWOT Analysis, 2016 202
  • Table 86: Fiasp SWOT Analysis, 2016 203
  • Table 87: Product Profile - Apidra 204
  • Table 88: Apidra SWOT Analysis, 2016 205
  • Table 89: Product Profile - Tresiba 207
  • Table 90: Tresiba SWOT Analysis, 2016 209
  • Table 91: Product Profile - Afrezza 211
  • Table 92: Afrezza SWOT Analysis, 2016 212
  • Table 93: Product Profile - Insulin glargine biosimilars 218
  • Table 94: Insulin Glargine Biosimilars SWOT Analysis, 2016 219
  • Table 95: Unmet Needs and Opportunities in T2D 222
  • Table 96: T2D - Clinical Trials by Phase and Status, 2016 232
  • Table 97: T2D - Phase Pipeline, 2016 234
  • Table 98: Comparison of Therapeutic Classes in Development for T2D, 2016 234
  • Table 99: Product Profile - Semaglutide 236
  • Table 100: Semaglutide SWOT Analysis, 2016 238
  • Table 101: Product Profile - OG217SC 239
  • Table 102: OG217SC SWOT Analysis, 2016 241
  • Table 103: Product Profile - ITCA 650 242
  • Table 104: ITCA 650 SWOT Analysis, 2016 245
  • Table 105: Product Profile - Ertugliflozin 246
  • Table 106: Ertugliflozin SWOT Analysis, 2016 248
  • Table 107: Product Profile - Sotagliflozin 250
  • Table 108: Sotagliflozin SWOT Analysis, 2016 252
  • Table 109: Product Profile - Bexagliflozin 253
  • Table 110: Bexagliflozin SWOT Analysis, 2016 255
  • Table 111: Key Companies in the T2D Market, 2016 258
  • Table 112: Other Companies in the T2D Market, 2016 259
  • Table 113: Eli Lilly's T2D Portfolio Assessment, 2016 264
  • Table 114: Eli Lilly SWOT Analysis, 2016 265
  • Table 115: Novo Nordisk's T2D Portfolio Assessment, 2016 267
  • Table 116: Novo Nordisk SWOT Analysis, 2016 268
  • Table 117: Sanofi's T2D Portfolio Assessment, 2016 270
  • Table 118: Sanofi SWOT Analysis, 2016 271
  • Table 119: AstraZeneca's T2D Portfolio Assessment, 2016 272
  • Table 120: AstraZeneca SWOT Analysis, 2016 273
  • Table 121: Merck's T2D Portfolio Assessment, 2016 274
  • Table 122: Merck SWOT Analysis, 2016 274
  • Table 123: BI's T2D Portfolio Assessment, 2016 275
  • Table 124: BI SWOT Analysis, 2016 276
  • Table 125: GSK's T2D Portfolio Assessment, 2016 277
  • Table 126: GSK SWOT Analysis, 2016 277
  • Table 127: Takeda's T2D Portfolio Assessment, 2016 279
  • Table 128: Takeda SWOT Analysis, 2016 279
  • Table 129: Roche's T2D Portfolio Assessment, 2016 280
  • Table 130: Roche SWOT Analysis, 2016 280
  • Table 131: Pfizer's T2D Portfolio Assessment, 2016 281
  • Table 132: Pfizer SWOT Analysis, 2016 282
  • Table 133: J&J's T2D Portfolio Assessment, 2016 283
  • Table 134: J&J SWOT Analysis, 2016 283
  • Table 135: Novartis' T2D Portfolio Assessment, 2016 284
  • Table 136: Novartis SWOT Analysis, 2016 284
  • Table 137: Intarcia Therapeutics' T2D Portfolio Assessment, 2016 285
  • Table 138: Intarcia Therapeutics SWOT Analysis, 2016 285
  • Table 139: Theracos' T2D Portfolio Assessment, 2016 285
  • Table 140: Theracos, SWOT Analysis, 2016 286
  • Table 141: T2D Market - Drivers and Barriers, 2016 290
  • Table 142: Key Events Impacting Sales for T2D in US, 2016-2026 293
  • Table 143: T2D Market - Drivers and Barriers in the US, 2016 294
  • Table 144: Key Events Impacting Sales for T2D in Germany, 2016-2026 297
  • Table 145: T2D Market - Drivers and Barriers in France, 2016 297
  • Table 146: Key Events Impacting Sales for T2D in Germany, 2016-2026 301
  • Table 147: T2D Market - Drivers and Barriers in Germany, 2016 301
  • Table 148: Key Events Impacting Sales for T2D in Italy, 2016-2026 305
  • Table 149: T2D Market - Drivers and Barriers in Italy, 2016 305
  • Table 150: Key Events Impacting Sales for T2D in Spain, 2016-2026 309
  • Table 151: T2D Market - Drivers and Barriers in Spain, 2016 309
  • Table 152: Key Events Impacting Sales for T2D in the UK, 2016-2026 313
  • Table 153: T2D Market - Drivers and Barriers in the UK, 2016 313
  • Table 154: Key Events Impacting Sales for T2D in Japan, 2016-2026 317
  • Table 155: T2D Market - Drivers and Barriers in Japan, 2016 318
  • Table 156: Key Launch Dates 359
  • Table 157: Key Patent Expiries 359
  • Table 158: Number of High-Prescribing Physicians Surveyed 373

List of Figures

1.2 List of Figures

  • Figure 1: Global Sales for T2D by Country/Region, 2016 and 2026 13
  • Figure 2: Company Portfolio Gap Analysis in T2D, 2016-2026 16
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016-2026 17
  • Figure 4: T2D Pathophysiology 27
  • Figure 5: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Men, Ages ≥20 Years, 2006-2026 34
  • Figure 6: 7MM, Age-Standardized Diagnosed Prevalence (%) of T2D , Women, Ages ≥20 Years, 2006-2026 35
  • Figure 7: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D 36
  • Figure 8: 7MM, Sources Used, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D 37
  • Figure 9: 7MM, Sources Used, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D 37
  • Figure 10: 7MM, Sources Used, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D 38
  • Figure 11: 7MM, Sources Used, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D 38
  • Figure 12: 7MM, Sources Used, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D 39
  • Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 49
  • Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2016 50
  • Figure 15: 7MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 51
  • Figure 16: 7MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 51
  • Figure 17: 7MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 52
  • Figure 18: 7MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 53
  • Figure 19: 7MM, Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, Both Sexes, N, 2016 54
  • Figure 20: Incretin and SGLT-2I Mechanisms of Action 62
  • Figure 21: ADA/EASD General Recommendations for Antihyperglycemic Therapy 63
  • Figure 22: Pipeline Agents in Develpoment for T2D 230
  • Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in T2D, 2016-2026 235
  • Figure 24: Company Portfolio Gap Analysis in T2D, 2016-2026 260
  • Figure 25: Global Sales for T2D by Country/Region, 2016 and 2026 289
  • Figure 26: Sales for T2D in the US by Drug Class, 2016 and 2026 292
  • Figure 27: Sales for T2D in the France by Drug Class, 2016 and 2026 296
  • Figure 28: Sales for T2D in the Germany by Drug Class, 2016 and 2026 300
  • Figure 29: Sales for T2D in the Italy by Drug Class, 2016 and 2026 304
  • Figure 30: Sales for T2D in the Spain by Drug Class, 2016 and 2026 308
  • Figure 31: Sales for T2D in the UK by Drug Class, 2016 and 2026 312
  • Figure 32: Sales for T2D in the Japan by Drug Class, 2016 and 2026 316
Back to Top